Dr. Singh on Dose Dense ACTHP in HER2+ Breast Cancer
February 7th 2020Jasmeet C. Singh, MD, discusses results from a retrospective analysis looking at the effectiveness of dose dense doxorubicin and cyclophosphamide followed by paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer.
Dr. Noy on the Rationale to Evaluate Devimistat in Burkitt Lymphoma
December 19th 2019Ariela Noy, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the rationale to evaluate devimistat (CPI-613) in patients with either Burkitt lymphoma/leukemia or high-grade B-cell lymphoma.